AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...
Roche Holding AG Akt-0.06% CHF238.35B ...
AbbVie (ABBV) announced that its board of directors has unanimously elected CEO Robert Michael to assume the additional position of chairman, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback